GlassScriptPhysician profile
Gregory M Cavanaugh
NPI 1124084462
$10,566.88
in general payments reported to CMS, 2019-2025
29 companies · $815 in 2025
The $815 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $2,516 · 2023: $5,709 · 2024: $528 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,625 · Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,625.00 |
| Food and Beverage | $1,426.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $7,650.00 | 2022-2023 | Painteq |
| Nevro Corp. | $434.65 | 2021-2024 | Senza |
| Spinal Simplicity, LLC | $418.44 | 2025 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $347.63 | 2021-2025 | Belbuca, Xtampza, Nucynta |
| Medtronic, INC. | $283.15 | 2021-2025 | Inceptiv |
| Boston Scientific Corporation | $207.28 | 2021 | |
| Electronic Waveform Lab, INC. | $165.65 | 2023-2024 | |
| Ibsa Pharma INC. | $126.83 | 2021-2025 | Tirosint, Licart, Flector |
| Janssen Pharmaceuticals, INC | $123.18 | 2024 | Spravato |
| Fidia Pharma USA INC. | $88.99 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.04 | 2022 | |
| Biodelivery Sciences International, INC. | $74.37 | 2021 | |
| Lilly USA, LLC | $62.80 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $59.74 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $49.27 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.77 | 2021-2022 | |
| Curonix LLC | $43.02 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Arbor Pharmaceuticals, INC. | $42.26 | 2021 | |
| Abbvie INC. | $39.83 | 2022 | |
| Pfizer INC. | $35.74 | 2024 | |
| Neuronetics, INC. | $29.92 | 2022 | |
| Pacira Therapeutics, INC. | $25.09 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.64 | 2023 | Ztlido |
| Grt US Holding, INC. | $22.28 | 2022 | |
| Orthogenrx INC. | $21.12 | 2021 | |
| Horizon Therapeutics Plc | $20.41 | 2021 | |
| Allergan, INC. | $19.26 | 2022 | |
| Valinor Pharma, LLC | $18.50 | 2025 | Movantik |
| Kowa Pharmaceuticals America, INC. | $13.02 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cavanaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.